Retrospective evaluation of premenopausal hormone‐sensitive breast cancer patients treated with adjuvant gonadotropin‐releasing hormone analogue: Anatolian Society of Medical Oncology (ASMO) study

Retrospective evaluation of premenopausal hormone‐sensitive breast cancer patients treated with... 1INTRODUCTIONBreast cancer is the most common malignancy and it ranks the first in cancer deaths in females. Adjuvant systemic therapies are used to reduce the risk of death and recurrence by eliminating residual and systemic micrometastases after local control in breast cancer. Disease recurrence is seen in 35–90% of lymph node positive patients and 10–30% of lymph node negative patients who receive only local treatment for occult micrometastatic disease.Selection between local and systemic therapies is done considering the different predictive and prognostic factors. Prognostic factors at the time of diagnosis give information about the course of the disease and the predictive factors give information about the probability of response to treatment that will be given. These factors include tumor histology, tumor size, and axillary lymph node status, hormone receptor status, human epidermal growth factor receptor (HER2) status, other concomitant diseases, age and menopausal status of the patient. Pathological assessment of tumor size, lymph node involvement, proliferation rate (Ki67), tumor grade peritumoral vascular invasion and age, endocrine receptor status, HER2 status of the patient are important predictive factors and guide the way in the choice of adjuvant treatment in early breast cancer. Expression of estrogen receptor (ER) and progesterone receptor http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Asia-Pacific Journal of Clinical Oncology Wiley

Retrospective evaluation of premenopausal hormone‐sensitive breast cancer patients treated with adjuvant gonadotropin‐releasing hormone analogue: Anatolian Society of Medical Oncology (ASMO) study

Loading next page...
 
/lp/wiley/retrospective-evaluation-of-premenopausal-hormone-sensitive-breast-lO0oCNSVJu
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 John Wiley & Sons Australia, Ltd
ISSN
1743-7555
eISSN
1743-7563
D.O.I.
10.1111/ajco.12685
Publisher site
See Article on Publisher Site

Abstract

1INTRODUCTIONBreast cancer is the most common malignancy and it ranks the first in cancer deaths in females. Adjuvant systemic therapies are used to reduce the risk of death and recurrence by eliminating residual and systemic micrometastases after local control in breast cancer. Disease recurrence is seen in 35–90% of lymph node positive patients and 10–30% of lymph node negative patients who receive only local treatment for occult micrometastatic disease.Selection between local and systemic therapies is done considering the different predictive and prognostic factors. Prognostic factors at the time of diagnosis give information about the course of the disease and the predictive factors give information about the probability of response to treatment that will be given. These factors include tumor histology, tumor size, and axillary lymph node status, hormone receptor status, human epidermal growth factor receptor (HER2) status, other concomitant diseases, age and menopausal status of the patient. Pathological assessment of tumor size, lymph node involvement, proliferation rate (Ki67), tumor grade peritumoral vascular invasion and age, endocrine receptor status, HER2 status of the patient are important predictive factors and guide the way in the choice of adjuvant treatment in early breast cancer. Expression of estrogen receptor (ER) and progesterone receptor

Journal

Asia-Pacific Journal of Clinical OncologyWiley

Published: Jan 1, 2018

Keywords: ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial